Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NEC Of Japan Teams With China Firm To Market Blood-Sugar Sensor

This article was originally published in PharmAsia News

Executive Summary

Japan's NEC said it is negotiating a marketing partnership with a company in China to develop a monitor for the nation's 100 million diabetics to use to follow their blood-sugar levels.

Japan's NEC said it is negotiating a marketing partnership with a company in China to develop a monitor for the nation's 100 million diabetics to use to follow their blood-sugar levels. The Japan firm said it expects to launch within a year its device that takes the vital measurement that works by pressing the palm against a sensor, no blood to be drawn. NEC said it is developing a follow-up product that also would analyze the data and inform the user. (Click here for more - a subscription may be required)

"NEC To Help China's Diabetics Take Charge Of Their Health" - Nikkei (Japan) (7/5/2014)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel